Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

Tamro appoints logistics director

Tamro Corporation, a wholesaler and distributor of pharmaceuticals, has appointed Aki Koskinen as logistics director.

Published By MarketLine
18 Dec 2014
NewsWire
NewsWire

Vermillion announces management changes

Vermillion, Inc., a bio-analytic solutions company, has named Valerie Palmieri, current COO as president and CEO, effective January 1, 2015.

Published By MarketLine
18 Dec 2014
NewsWire
NewsWire

Sunesis announces favorable results from Phase III acute myeloid leukemia trial

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, has announced the results from Phase III VALOR trial of vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia, or AML.

Published By MarketLine
18 Dec 2014
NewsWire
NewsWire

Spectral Diagnostics announces name change to Spectral Medical

Spectral Diagnostics Inc., a developer of treatment for patients with septic shock, has announced its name change to Spectral Medical Inc., effective December 31, 2014.

Published By MarketLine
18 Dec 2014
NewsWire
NewsWire

OncoCyte completes enrollment in urine-based bladder cancer test study

BioTime, Inc. and its subsidiary OncoCyte Corporation have announced that OncoCyte has completed enrollment in the initial clinical study of its urine-based bladder cancer diagnostic test.

Published By MarketLine
17 Dec 2014
NewsWire
NewsWire

Seattle and Takeda announce favorable data from Phase III lymphoma trial

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited have announced data from Phase III AETHERA trial, which demonstrates that Hodgkin lymphoma, or HL, patients at risk of relapse following an autologous stem cell transplant, or ASCT, who received ADCETRIS, or brentuximab vedotin, as consolidation therapy immediately after ASCT had significant improvement in progression-free survival, or PFS, compared to patients who received placebo.

Published By MarketLine
17 Dec 2014
NewsWire
NewsWire

Merck announces encouraging data from breast cancer study

Merck has announced early study findings demonstrating an overall response rate of 18.5 percent with KEYTRUDA, the company's anti-PD-1 therapy, as assessed by RECIST v1.1, central review, or n=5/27, in PD-L1 positive, advanced triple-negative breast cancer.

Published By MarketLine
17 Dec 2014
NewsWire
NewsWire

WellPoint announces availability of new e-learning tool

WellPoint, Inc., a health benefit company, has partnered with Critical Measures to offer Viewpoints, a new e-learning resource for physicians that reportedly presents case studies and methods for applying evidence-based guidelines in a globally connected and mobile world.

Published By MarketLine
17 Dec 2014
NewsWire
NewsWire

Apricus Biosciences appoints chief medical officer

Apricus Biosciences, Inc., a biopharmaceutical company, has appointed Barbara Troupin as the company's chief medical officer.

Published By MarketLine
17 Dec 2014
NewsWire
NewsWire

Lundbeck and Otsuka receive FDA approval for labeling update of aripiprazole

H. Lundbeck A/S and Otsuka Pharmaceutical Co. have received the FDA approval for the labeling update of Abilify Maintena, or aripiprazole, for extended-release injectable suspension, which is indicated for the treatment of schizophrenia.

Published By MarketLine
17 Dec 2014

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.